Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis
10.19401/j.cnki.1007-3639.2024.07.009
- VernacularTitle:鞘内注射治疗实体瘤脑膜转移的临床研究进展
- Author:
Sijie HUANG
1
;
Xun KANG
;
Wenbin LI
Author Information
1. 首都医科大学附属北京天坛医院神经肿瘤综合治疗中心,北京 100070
- Keywords:
Leptomeningeal metastasis;
Intrathecal therapy;
Chemotherapy;
Targeted therapy;
Immunotherapy
- From:
China Oncology
2024;34(7):695-701
- CountryChina
- Language:Chinese
-
Abstract:
Leptomeningeal metastasis(LM)is a serious late complication in patients with solid tumors,which is common in patients with lung cancer,breast cancer and melanoma.In recent years,due to the progress of diagnosis,the diagnosis rate of LM has gradually increased.The main goal of the therapy is to maintain neurological function,improve the quality of life and the overall survival rate,and prolong the progression-free survival time of patients.Intrathecal therapy is one of the main treatments for LM,which can deliver drugs directly to the subarachnoid space.The traditional intrathecal drugs are methotrexate,cytarabine and thiotepa.With the development of new research,a variety of chemotherapeutic drugs,targeted drugs and immune checkpoint inhibitors have also been used in intrathecal therapy.In addition,different ways of intrathecal administration also bring new hope to patients.This article reviewed the clinical research progress of intrathecal therapy in the treatment of LM.
